Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism Disorders

Interventions

DRUG

Pf-05175157

200-mg administered twice daily for 14 days

DRUG

placebo

placebo administered twice daily for 14 days

DRUG

midazolam

midazolam 3-mg admistered as single doses on Day 0 and Day 11.

Trial Locations (1)

Pfizer Investigational Site, South Miami